Brielle Benyon

Articles

Study highlights positive real-world outcomes with tivozanib in frontline mRCC

February 20, 2022

First-line tivozanib in patients with metastatic renal cell carcinoma was reported to be safe, tolerable, and capable of producing similar clinical activity as other tyrosine kinase inhibitors used in this setting.